Formulation Development
Moderna Announces First Participant Dosed in Phase 1 Study of its Epstein-Bar Virus Vaccine
Moderna, Inc. recently announced the first participant has been dosed in the Phase 1 study of mRNA-1189, the Company's Epstein-Barr Virus (EBV) vaccine candidate. The study…
PhoreMost & POLARISqb Announce a Multi-Target Collaboration to Investigate Next-Generation Cancer Therapies
PhoreMost Limited and Polaris Quantum Biotech recently announced a collaboration to study oncology targets currently considered undruggable. Under the terms of the agreement, the POLARISqb…
MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases
MannKind Corporation recently announced that has extended its collaboration with Thirona Bio, Inc. with the purchase of a second convertible note issued by Thirona, and the appointment of….
Pfizer & BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine
Pfizer Inc. and BioNTech SE recently announced a new research, development, and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles….
Akoya Biosciences & Bio-Techne Partner to Deliver Automated Spatial Multiomics Workflow With Industry-Leading Speed & Resolution
Akoya Biosciences, Inc. and Bio-Techne recently announced a partnership to develop the first single-cell, spatial multiomics workflow for comprehensive, unbiased analysis of tissue samples. Through…
Rain Therapeutics & Roche to Collaborate on Clinical Trial of Milademetan Combination With Anti-PD-L1 Immunotherapy for Various Solid Tumor Indications
Rain Therapeutics Inc. recently announced a clinical supply agreement with Roche for the supply of the anti-Programmed Death Ligand-1 (PD-L1) monoclonal antibody, atezolizumab…..
F-star Therapeutics Announces Merck KGaA, Darmstadt, Germany Exercises a Fourth Licensing Option in Immuno-Oncology Collaboration
F-star Therapeutics, Inc. recently announced that Ares Trading S.A., an affiliate of Merck KGaA, Darmstadt, Germany, has exercised a fourth licensing option to develop another…
Cue Biopharma & LG Chem Life Sciences Announce Development Milestone in Immuno-STAT Biologics Collaboration for CUE-102
Cue Biopharma, Inc. and LG Chem Life Sciences recently announced a key milestone in the selection of a clinical product candidate has been reached in their collaboration for CUE-102, an Immuno-STAT biologic, jointly developed to….
Curia Unveils Comprehensive mRNA Solution
Curia, formerly AMRI, a leading contract research, development and manufacturing organization, recently unveiled its messenger RNA (mRNA) solution, which includes discovery, process development and mRNA drug substance production, through….
Metrics Contract Services Appoints Commercial Manufacturing BD Lead
Metrics Contract Services, a full-service contract development and manufacturing organization (CDMO) in novel oral solid dose (OSD) products, has appointed Kim Black-Washington as Senior Business…
Santhera Enters Exclusive License Agreement With Sperogenix for Vamorolone in Rare Diseases in the Greater China Region
Santhera Pharmaceuticals recently announced it has entered into an exclusive license agreement with Sperogenix Therapeutics, a China-based company specializing in orphan diseases. Under this agreement….
Viridian Therapeutics Submits IND Application for VRDN-002 to the US FDA
Viridian Therapeutics, Inc. recently announced the submission of an investigational new drug (IND) application to the US FDA for VRDN-002, a humanized monoclonal antibody that…
FDA Grants Breakthrough Therapy Designation for Cullinan Oncology’s CLN-081 in Patients With Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Cullinan Oncology, Inc. recently announced the US FDA has granted Breakthrough Therapy Designation for CLN-081 for the treatment of patients with locally advanced or metastatic…
TCR² Therapeutics & Arbor Biotechnologies Establish Collaboration to Advance Allogeneic TRuC-T Cell Therapies
TCR2 Therapeutics Inc. and Arbor Biotechnologies recently announced the two companies have entered into a strategic research collaboration and non-exclusive license agreement focused on the…
Biogen Exercises Option With Ionis to Develop & Commercialize Investigational ASO for SMA
Biogen Inc. and Ionis Pharmaceuticals, Inc. recently announced that Biogen exercised its option to obtain from Ionis a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB115/ION306…..
Centogene’s CentoCloud Set to Revolutionize Rare Disease Diagnostics With Decentralized SaaS Platform for Laboratories Around the World
Centogene N.V. recently announced the global release of CentoCloud, a SaaS platform enabling decentralized analysis, interpretation, and reporting of genomic variants linked to rare diseases.…
Vaccinex Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda & Pepinemab in Patients With Advanced, Recurrent, or Metastatic Head & Neck Squamous Cell Carcinoma Passes Planned Interim Safety Analysis
The Phase 2 segment of the study is now expected to begin enrollment and is expected to accelerate patient accrual…..
Assembly Biosciences Outlines Anticipated 2022 Pipeline Development Milestones
Assembly Biosciences, Inc. recently outlined anticipated progress and milestones for its development pipeline in 2022…..
Inotiv, Inc. & Synexa Life Sciences Sign Letter of Intent to Establish Center of Excellence for Biotherapeutics & Biomarkers
Inotiv, Inc. and Synexa Life Sciences recently announced they intend to form a collaboration that will accelerate Inotiv’s development of biomarkers essential to the understanding of safety and efficacy of novel biotherapeutics, enhancing the….
Ovid Therapeutics Expands Epilepsy Franchise With Novel KCC2 Activators
Ovid Therapeutics Inc. recently announced the company has entered into an exclusive license agreement with AstraZeneca for a library of early stage small molecules targeting…